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Introduction 
Alzheimer’s disease (AD) is a progressive 
neurodegenerative disease that primarily affects 
individuals above the age of 65 and is often 
associated with memory loss, one of its chief 
symptoms. Although it was first discovered by 
Alois Alzheimer in 1906, AD has only recently 
garnered attention proportionate to the impact 
it is expected to have as the world’s population 
ages at increasing rates (National Institute 
on Aging, 2016). Despite the certainty of this 
its importance, there is much the medical and 
scientific communities do not know about the 
etiology of this disease. This paper will discuss a 
few of the reasons for this lack of knowledge by 
specifically describing the definite but unclear 
influence of genetics and pathology on the 
clinical symptoms of AD.
As previously mentioned, its hallmark 
symptom is memory loss, specifically the 
inability to retain novel information (National 
Institute on Aging, 2016). Other symptoms 
include disorientation, problems with speaking 
and swallowing, and behavioral changes, the 
last of which are often the most burdensome 
on the individual’s relationships with others 
(National Institute on Aging, 2016). AD is the 
most common type of dementia, and currently 
affects over 5 million Americans (National 
Institute on Aging, 2016). 
Understanding the Disease
Given its current and expected future 
prevalence, there is a clear need for an 
understanding of the underlying causes of 
this disease, for it is what occurs within 
(and beyond) the human body that leads to 
these devastating symptoms. Indeed, many 
researchers have responded swiftly to this 
call to arms: a search on PubMed’s database 
using the keywords “Alzheimer’s disease” 
indicated that 7,617 articles were published on 
this topic in 2016 alone. Despite this recently 
demonstrated scientific interest, the largest 
questions of influence remain. Two of the major 
questions that will be explored in this paper 
involve pathology and genetics.
Questions about the influence of a disease’s 
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Figure 1: High magnification 
micrograph showing 
Alzheimer type II astrocytes.
Source: Wikimedia Commons 
(Credit: Nephron)
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pathology often seem unnecessary, for it is the 
very study that is pathology seeks to explain 
the causes of clinical symptoms. But when the 
nature of the pathology itself is complex, the 
matter becomes more complicated. Here, the 
symptoms of AD are caused by the large-scale 
death of neuronal cells in the brain, causing 
what often appears to be a shrunken version of 
the “normal” human brain (National Institute on 
Aging, 2016). However, what is the cause (i.e. 
pathogenesis) of this sweeping cell loss? When, 
how, and why does this pathology result? While 
there are no definite answers to this question, 
many experts would bring up two compounds 
with measurable physical presence in the brains 
of those with AD: amyloid-beta and tau, often 
collectively deemed, “plaques and tangles.” 
Despite their noted association with AD, these 
proteins have been subject to many questions 
their specific influence. Amyloid-beta has 
received the majority of the attention, and will 
be further described below.  
Amyloid-beta (Aβ) is a protein found in the 
form of extracellular plaques, and is thought 
to be largely unique to AD (Agamanolis, 2016). 
Over a century since the disease’s discovery, the 
detection of Aβ is still used to make a definitive 
diagnosis upon autopsy because. Barring recent 
technological advances, there has not existed a 
means of observing these plaques in living tissue. 
Despite not offering diagnostic assistance, this 
method of studying Aβ has allowed scientists 
to characterize the protein and has resulted 
in a few important claims frequently made. 
First, Aβ is a transmembrane protein that is 
also a segment of a much larger protein called 
Amyloid Precursor Protein (APP), whose 
function in the body has yet to be determined 
(Agamanolis, 2016). When APP is improperly 
cleaved by a pair of enzymes, the product is 
Aβ, which is then able to accumulate and form 
among cells. In addition to simply accumulating 
in the brain, Aβ is also dangerous to neurons 
in a few specific ways. First, it disrupts long 
term potentiation, a process that strengthens 
connections between communicating neurons 
(Purves et al., 2001). Second, it harms synapses, 
the physical spaces that link neurons (Purves et 
al., 2001). Ultimately, the toxicity of Aβ plaques 
can result in death of neurons specifically in 
areas of the brain associated with functions 
impaired by AD (Agamanolis, 2016). The entire 
process, beginning with APP and ending with 
Figure 2: Auguste D, the first 
patient diagnosed with the 
disease that would come to 
be named after the physician 
Alois Alzheimer.
Source: Wikimedia Commons
Figure 3: Amyloid-beta 
plaques observed in the 
brain of an individual with 
Alzheimer’s disease.
Source: Wikimedia Commons 
(Credit: User KGH)
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“Perhaps the most 
surprising is that 
up to 40% of elderly 
without dementia 
have been shown 
to possess AD 
pathology.”
failure rate of 99.6% (Burke, 2014). Furthermore, 
these pharmaceuticals often seem to remove 
the physical traces of Aβ plaques in affected 
individuals, yet their symptoms remain. To 
explain this finding, some have essentially argued 
that removing amyloid after clinical symptoms 
emerge is too late, and that if these drugs were 
administered earlier, perhaps they would have 
more success (Burke, 2014). Using this same 
reasoning, the finding above—that individuals 
without dementia can also show pathology—
can also be explained: maybe these individuals 
were on track to develop symptomatic AD had 
they not died before its onset (Morris, Clark, & 
Vissel, 2014). This assertion is complicated, and 
almost every claim or theory in this field, calls 
for additional refinement.
In a related vein, there are many important 
questions regarding the influence of genetics 
on the development of AD symptoms. The role 
of genetics cannot be adequately explained 
without first understanding the division 
between two types of Alzheimer’s disease: early 
onset (EOAD) and late onset (LOAD). EOAD 
comprises roughly 5% of all AD cases, and can 
affect individuals at a much younger age range 
than LOAD (Agamanolis, 2016). Beyond the 
time of onset, these subtypes differ primarily in 
their connections with genetics: EOAD has been 
found to be caused genetic mutations, whereas 
no such causal link has been found for LOAD 
(Hutton, Pérez-Tur, & Hardy, 1998). 
Specifically, EOAD is caused by mutations 
in the genes that directly affect Aβ production. 
One set of mutations is on the gene that codes 
for APP itself, a gene found on chromosome 
21; another, more common variety, involves 
mutations are on two presenilin genes on 
chromosome 14, genes that are thought to 
clinical symptoms of AD, is often called the 
“amyloid cascade hypothesis.”
Weaknesses of the Amyloid 
Cascade Hypothesis
Despite this logical link, there are a few 
critical findings that the amyloid cascade 
hypothesis has been unable to explain thus far. 
Perhaps the most surprising is that up to 40% 
of elderly without dementia have been shown 
to possess AD pathology (Morris, Clark, & 
Vissel, 2014), sometimes including Aβ at levels 
comparable to those of individuals with clinical 
symptoms of dementia (Swerdlow, 2007). How 
is this consistent with the link clearly explained 
by the amyloid cascade hypothesis? There 
are several possibilities. One is that there are 
multiple forms of Aβ, and only one—or some—is 
responsible for symptoms. Another is that Aβ 
does not actually cause symptoms at all, but is 
instead produced by the process that does cause 
them (Morris, Clark, & Vissel, 2014). Yet another 
option is that other factors, perhaps external 
to the brain, counteract the development of 
symptoms that would normally occur due 
to Aβ accumulation. This third possibility is 
heavily implicated with the theory of “cognitive 
reserve,” which suggests that individuals may 
accrue tolerance for AD pathology over time 
based on various lifestyle features (Morris, 
Clark, & Vissel, 2014). 
Clearly, this finding indicates a need for 
resolution among experts. Another finding 
making a similar demand is the high failure rate 
of pharmaceutical drug trials that take as their 
basis the influence of Aβ. A study examining 
drug trials between 2002 and 2012 determined 
out of 244 Alzheimer’s drugs tested in 413 trials, 
only one was eventually approved, resulting in a 
Figure 4: A healthy brain (left) 
compared with the shrunken 
brain characteristic of 
Alzheimer’s disease (right).
Source: Wikimedia Commons 
(Credit: Garrondo)
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also influence Aβ production (Hutton, Pérez-
Tur, & Hardy, 1998). Thus, through direct or 
indirect impact, these mutations in EOAD are 
themselves crucial for the maintenance of the 
amyloid cascade hypothesis. Furthermore, 
they are inherited in an autosomal dominant 
pattern, meaning that only one inherited copy 
is sufficient for an offspring to develop the 
disease (Hutton, Pérez-Tur, & Hardy, 1998). 
The complexity emerges, however, when 
examining the other 95% of AD cases, for this 
straightforward pattern ceases to hold in LOAD. 
Thus far, no genetic mutations have found to be 
definitive causes of LOAD; instead, researchers 
have been able to identify a susceptibility gene: 
ApoE. 
ApoE controls production of the ApoE 
protein, which is thought to be involved in 
repairing the brain after damage (Hutton, Pérez-
Tur, & Hardy, 1998). It is found on chromosome 
19 and exists in three forms, or alleles: ϵ2, ϵ3, 
and ϵ4. Of these, the ϵ4 allele has been shown 
to increase susceptibility of AD, and to do so 
in a “dose-dependent manner,” meaning that 
inheriting two copies of this allele increases 
risk more than inheriting one copy (Ertekin-
Taner, 2007). This was demonstrated in a study 
that found that 55% of subjects with two copies 
developed AD by age 80, compared with 27% of 
subjects with an ϵ3/ ϵ4 pair, and with 9% of those 
with two copies of ϵ3 (Ertekin-Taner, 2007).
Conclusion
Although this evidence is quite compelling, 
there are nevertheless unanswered questions. 
One concerns the heterogeneity of ApoE’s 
influence. Specifically, most studies conducted—
including the one mentioned above—
predominantly rely on Caucasian subjects. 
Studies that have focused on African-American 
and Hispanic populations have found a much 
weaker association, or even no association at all 
in some cases (Ertekin-Taner, 2007). Researchers 
have hypothesized that this observation could 
be due to genetic and environmental factors 
and interactions that affect distinct populations 
differently. Ultimately, it has been estimated 
that the ApoE ϵ4 allele imparts a risk of 20-
70%, a range that evokes the uncertainty 
characterizing not only this issue but the field in 
general (Ertekin-Taner, 2007).
The questions that arise in determining the 
cause(s) of AD are complicated and multifaceted. 
Those involving pathogenesis and genetics are 
some of the most studied, but do not exhaust all 
the avenues of inquiry researchers and clinicians 
are taking. For example, many have turned 
towards a closer examination of environmental 
factors, and others have chosen to focus not 
on the causality of AD but rather on equally 
important questions regarding the quality of 
life of those living with dementia. Each area is 
critical in understanding this highly complex 
and common disease, and one can hope that 
with resources, time, creativity, and persistence, 
strides can be made in the near future. 
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rely on Caucasian 
subjects.”
Figure 5: A typical brain 
image taken using Positron 
Emission Tomography (PET) of 
an individual with Alzheimer’s 
disease.
Source: Wikimedia Commons 
(Credit: National Institutes of 
Health)
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